Drug
Bupivacaine
Bupivacaine: highest development phase Post-Market, developed by Fresenius Kabi, Heron Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Fresenius Kabi, Heron Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Bupivacaine Hydrochloride NCT05109312 | Post-Market | Analgesia |
| Bupivacaine HCl NCT03705065 | Post-Market | Postoperative Pain |
| SENSORCAINE MPF | Approved |
Latest
Follow Bupivacaine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.